In vivo selection of tumor-targeting RNA motifs

Mi, Jing; Liu, Yingmiao; Rabbani, Zahid N.; Yang, Zhongguang; Urban, Johannes; Sullenger, Bruce A.; Clary, Bryan M.

doi:10.1038/nchembio.277

Cited by 245 publications

(206 citation statements)

References 18 publications

Supporting

Mentioning

204

Contrasting

Unclassified

Order By: Relevance

“…We applied a positive/negative in vitro SELEX approach to the secretomes of a pancreatic cancer cell line (MiaPaCa-2) and a normal pancreatic cell line (HPDE) with the goal of identifying protein molecules that are preferentially secreted by pancreatic cancer cells. Selections against a variety of complex targets have been performed in studies using whole cancer cells in culture (23)(24)(25)(26)(27) and whole tumors in vivo (28) to generate aptamers against proteins that are expressed on the cancer cell surface and which may represent novel targets for imaging or therapy. Our selection against secreted proteins resulted in the identification of three dominant RNA sequences with distinct binding targets, including one, M9-5, that preferentially bound the MiaPaCa-2 secretome over the HPDE secretome.…”

Section: Discussionmentioning

confidence: 99%

Comparing human pancreatic cell secretomes by in vitro aptamer selection identifies cyclophilin B as a candidate pancreatic cancer biomarker

Ray¹,

Rialon-Guevara²,

Veras³

et al. 2012

J. Clin. Invest.

View full text Add to dashboard Cite

Most cases of pancreatic cancer are not diagnosed until they are no longer curable with surgery. Therefore, it is critical to develop a sensitive, preferably noninvasive, method for detecting the disease at an earlier stage. In order to identify biomarkers for pancreatic cancer, we devised an in vitro positive/negative selection strategy to identify RNA ligands (aptamers) that could detect structural differences between the secretomes of pancreatic cancer and non-cancerous cells. Using this molecular recognition approach, we identified an aptamer (M9-5) that differentially bound conditioned media from cancerous and non-cancerous human pancreatic cell lines. This aptamer further discriminated between the sera of pancreatic cancer patients and healthy volunteers with high sensitivity and specificity. We utilized biochemical purification methods and mass-spectrometric analysis to identify the M9-5 target as cyclophilin B (CypB). This molecular recognition-based strategy simultaneously identified CypB as a serum biomarker and generated a new reagent to recognize it in body fluids. Moreover, this approach should be generalizable to other diseases and complementary to traditional approaches that focus on differences in expression level between samples. Finally, we suggest that the aptamer we identified has the potential to serve as a tool for the early detection of pancreatic cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparing human pancreatic cell secretomes by in vitro aptamer selection identifies cyclophilin B as a candidate pancreatic cancer biomarker

Ray¹,

Rialon-Guevara²,

Veras³

et al. 2012

J. Clin. Invest.

View full text Add to dashboard Cite

show abstract

“…[498,534] Finding more efficient aptamers for specific applications, they have also been selected in vivo by Mi et al in 2010. [535] Aptamers have gained a lot interest in numerous cancer diagnostics and therapeutics over the past few years. [536] They have been represented as promising candidates of targeting ligands due to their incredible degree of versatility for binding to a wide variety of targets, such as proteins, [537] small molecules, [538] and carbohydrates.…”

Section: Aptamersmentioning

confidence: 99%

Synthesis, Functionalization, and Design of Magnetic Nanoparticles for Theranostic Applications

Mosayebi

Kiyasatfar

Laurent

2017

Adv Healthcare Materials

185

165

View full text Add to dashboard Cite

In order to translate nanotechnology into medical practice, magnetic nanoparticles (MNPs) have been presented as a class of non‐invasive nanomaterials for numerous biomedical applications. In particular, MNPs have opened a door for simultaneous diagnosis and brisk treatment of diseases in the form of theranostic agents. This review highlights the recent advances in preparation and utilization of MNPs from the synthesis and functionalization steps to the final design consideration in evading the body immune system for therapeutic and diagnostic applications with addressing the most recent examples of the literature in each section. This study provides a conceptual framework of a wide range of synthetic routes classified mainly as wet chemistry, state‐of‐the‐art microfluidic reactors, and biogenic routes, along with the most popular coating materials to stabilize resultant MNPs. Additionally, key aspects of prolonging the half‐life of MNPs via overcoming the sequential biological barriers are covered through unraveling the biophysical interactions at the bio–nano interface and giving a set of criteria to efficiently modulate MNPs' physicochemical properties. Furthermore, concepts of passive and active targeting for successful cell internalization, by respectively exploiting the unique properties of cancers and novel targeting ligands are described in detail. Finally, this study extensively covers the recent developments in magnetic drug targeting and hyperthermia as therapeutic applications of MNPs. In addition, multi‐modal imaging via fusion of magnetic resonance imaging, and also innovative magnetic particle imaging with other imaging techniques for early diagnosis of diseases are extensively provided.

show abstract

“…Then we can figure out that p68 is involved in preparing fundamental conformational change for migration cells. p68 could also regulate invasiveness of cancer cells by interacting with other factors, including COUP-TFI in breast cancer [88] and a specific RNA aptamer in colon cancer [89]. A class of anticancer drugs histone deacetylase inhibitors (HDACIs), was found to have the ability to induce tumor cell EMT via the overaccumulation of Snail [90].…”

Section: Post-translational Modification Of P68 In Cancer Developmentmentioning

confidence: 99%

P68 RNA helicase as a molecular target for cancer therapy

Dai

Cao

Yang

et al. 2014

J Exp Clin Cancer Res

View full text Add to dashboard Cite

The DEAD-box family of RNA helicase is known to be required in virtually all cellular processes involving RNA, and p68 is a prototypic one of the family. Reports have indicated that in addition to ATPase and RNA helicase ability, p68 can also function as a co-activator for transcription factors such as estrogen receptor alpha, tumor suppressor p53 and beta-catenin. More than that, post-translational modification of p68 including phosphorylation, acetylation, sumoylation, and ubiquitylation can regulate the coactivation effect. Furthermore, aberrant expression of p68 in cancers highlights that p68 plays an important role for tumorgenesis and development. In this review, we briefly introduce the function and modulation of p68 in cancer cells, and put forward envisagement about future study about p68.

show abstract

In vivo selection of tumor-targeting RNA motifs

Cited by 245 publications

References 18 publications

Comparing human pancreatic cell secretomes by in vitro aptamer selection identifies cyclophilin B as a candidate pancreatic cancer biomarker

Comparing human pancreatic cell secretomes by in vitro aptamer selection identifies cyclophilin B as a candidate pancreatic cancer biomarker

Synthesis, Functionalization, and Design of Magnetic Nanoparticles for Theranostic Applications

P68 RNA helicase as a molecular target for cancer therapy

Contact Info

Product

Resources

About